Company intelligence / Profile preview

Nautilus Biotechnology

Seattle, Washington, United Statesnautilus.bio ↗

Ownership: Private
Employees: ~133
Development stage: Other

Overview

Nautilus Biotechnology is developing a single-molecule proteomics platform designed to enable high-resolution quantification and analysis of entire human proteomes, with the goal of transforming drug development and biomarker discovery. As of early 2025, their system remains in development, targeting commercial availability in late 2026.

Modalities: Platform technologyProteinProteoform analysis
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Nautilus Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nautilus Biotechnology.